AdultPediatricDosage Forms & Strengths injection, lyophilized powder for reconstitution 200mg/vial injectable solution, single-dose prefilled syringe 200mg/mL Crohn Disease Indicated for maintaining clinical response in patients with moderate to severe active disease who had an inadequate response to conventional therapy Initial: 400 mg SC (2 injections of 200 mg), repeat at 2 and 4 weeks Maintenance: 400 mg SC q4Weeks Rheumatoid Arthritis Indicated for moderate to severe active rheumatoid arthritis (RA) Initial: 400 mg SC (2 injections of 200 mg), repeat at 2 and 4 weeks Maintenance: 200 mg SC q2Weeks OR 400 mg SC q4Weeks Psoriatic Arthritis Indicated for active psoriatic arthritis (PsA) Initial: 400 mg SC (2 injections of 200 mg), repeat at 2 and 4 weeks, followed by 200 mg SC q2Weeks Maintenance: Consider 400 mg SC q4Weeks Ankylosing Spondylitis Indicated for active ankylosing spondylitis (AS) Initial: 400 mg SC (2 injections of 200 mg), repeat at 2 and 4 weeks Maintenance: 200 mg SC q2Weeks OR 400 mg SC q4weeks Spondyloarthritis Indicated for active nonradiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation Initial: 400 mg SC (2 injections of 200 mg), repeat at 2 and 4 weeks Maintenance: 200 mg SC q2Weeks OR 400 mg SC q4Weeks Plaque Psoriasis Indicated for moderate-to-severe plaque psoriasis (PsO) in patients who are candidates for systemic therapy or phototherapy 400 every other week For some patients (≤90 kg), consider starting at 400 mg SC (given as 2 injections of 200 mg each) initially and at Weeks 2 and 4, followed by 200 mg SC every other weekSafety and efficacy not establishedInteraction CheckerEnter a drug name and certolizumab pegolNo Results No Interactions Found Interactions FoundContraindicatedSerious - Use AlternativeSignificant - Monitor CloselyMinorAll Interactions Sort By: SeverityName Contraindicated (13)adenovirus types 4 and 7 live, oralcertolizumab pegol decreases effects of adenovirus types 4 and 7 live, oral by pharmacodynamic antagonism. Contraindicated. Do not give live vaccines concurrently with certolizumab.BCG intravesical livecertolizumab pegol decreases effects of BCG intravesical live by pharmacodynamic antagonism. Contraindicated. Do not give live vaccines concurrently with certolizumab.BCG vaccine livecertolizumab pegol decreases effects of BCG vaccine live by pharmacodynamic antagonism. Contraindicated. Do not give live vaccines concurrently with certolizumab.influenza virus vaccine quadrivalent, intranasalcertolizumab pegol decreases effects of influenza virus vaccine quadrivalent, intranasal by pharmacodynamic antagonism. Contraindicated. Do not give live vaccines concurrently with certolizumab.measles mumps and rubella vaccine, livecertolizumab pegol decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Contraindicated. Do not give live vaccines concurrently with certolizumab.measles, mumps, rubella and varicella vaccine, livecertolizumab pegol decreases effects of measles, mumps, rubella and varicella vaccine, live by pharmacodynamic antagonism. Contraindicated. Do not give live vaccines concurrently with certolizumab.rotavirus oral vaccine, livecertolizumab pegol decreases effects of rotavirus oral vaccine, live by pharmacodynamic antagonism. Contraindicated. Do not give live vaccines concurrently with certolizumab.smallpox (vaccinia) vaccine, livecertolizumab pegol decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Contraindicated. Do not give live vaccines concurrently with certolizumab.typhoid vaccine livecertolizumab pegol decreases effects of typhoid vaccine live by pharmacodynamic antagonism. Contraindicated. Do not give live vaccines concurrently with certolizumab.upadacitinibcertolizumab pegol, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.varicella virus vaccine livecertolizumab pegol decreases effects of varicella virus vaccine live by pharmacodynamic antagonism. Contraindicated. Do not give live vaccines concurrently with certolizumab.yellow fever vaccinecertolizumab pegol decreases effects of yellow fever vaccine by pharmacodynamic antagonism. Contraindicated. Do not give live vaccines concurrently with certolizumab.zoster vaccine livecertolizumab pegol decreases effects of zoster vaccine live by pharmacodynamic antagonism. Contraindicated. Do not give live vaccines concurrently with certolizumab.Serious - Use Alternative (24)abataceptabatacept and certolizumab pegol both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid combination because of an increased risk of serious infection.adalimumabadalimumab and certolizumab pegol both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid combination because of an increased risk of serious infection.anakinraanakinra and certolizumab pegol both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid combination because of an increased risk of serious infection.axicabtagene ciloleucelcertolizumab pegol, axicabtagene ciloleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.baricitinibbaricitinib, certolizumab pegol. Either increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Baricitinib is not recommended in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressives.brexucabtagene autoleucelcertolizumab pegol, brexucabtagene autoleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.ciltacabtagene autoleucelcertolizumab pegol, ciltacabtagene autoleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.etanerceptetanercept and certolizumab pegol both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid combination because of an increased risk of serious infection.golimumabgolimumab and certolizumab pegol both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid combination because of an increased risk of serious infection.human papillomavirus vaccine, nonavalentcertolizumab pegol decreases effects of human papillomavirus vaccine, nonavalent by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs, and corticosteroids (used in greater than physiologic doses), may reduce the immune responses to vaccines.human papillomavirus vaccine, quadrivalentcertolizumab pegol decreases effects of human papillomavirus vaccine, quadrivalent by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs, and corticosteroids (used in greater than physiologic doses), may reduce the immune responses to vaccines.idecabtagene vicleucelcertolizumab pegol, idecabtagene vicleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.infliximabinfliximab and certolizumab pegol both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid combination because of an increased risk of serious infection.influenza virus vaccine quadrivalent, adjuvantedcertolizumab pegol decreases effects of influenza virus vaccine quadrivalent, adjuvanted by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressive drugs may reduce the immune response to influenza vaccine.influenza virus vaccine trivalent, adjuvantedcertolizumab pegol decreases effects of influenza virus vaccine trivalent, adjuvanted by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressive drugs may reduce the immune response to influenza vaccine.lisocabtagene maraleucelcertolizumab pegol, lisocabtagene maraleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.natalizumabnatalizumab and certolizumab pegol both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid combination because of an increased risk of serious infection.rilonaceptrilonacept and certolizumab pegol both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid combination because of an increased risk of serious infection.rituximabrituximab and certolizumab pegol both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid combination because of an increased risk of serious infection.rituximab-hyaluronidaserituximab-hyaluronidase and certolizumab pegol both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid combination because of an increased risk of serious infection.tisagenlecleucelcertolizumab pegol, tisagenlecleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.tocilizumabtocilizumab and certolizumab pegol both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid combination because of an increased risk of serious infection.tofacitinibcertolizumab pegol, tofacitinib. Either increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.vedolizumabvedolizumab and certolizumab pegol both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid coadministration of vedolizumab with TNF blockers because of the potential for increased risk of infectionsMonitor Closely (44)anthrax vaccine adsorbedcertolizumab pegol decreases effects of anthrax vaccine adsorbed by pharmacodynamic antagonism. Use Caution/Monitor.belataceptbelatacept and certolizumab pegol both increase immunosuppressive effects; risk of infection. Use Caution/Monitor.cholera vaccinecertolizumab pegol decreases effects of cholera vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs and corticosteroids (used in greater than physiologic doses), may reduce the immune response to cholera vaccine.dengue vaccinecertolizumab pegol decreases effects of dengue vaccine by immunosuppressive effects; risk of infection. Use Caution/Monitor. Immunosuppressive therapies (eg, irradiation, antimetabolites, alkylating agents, cytotoxic drugs, corticosteroids [greater than physiologic doses]) may reduce immune response to dengue vaccine.denosumabcertolizumab pegol, denosumab. Other (see comment). Use Caution/Monitor. Comment: Caution should be taken in patients on concomitant immunosuppressants or with impaired immune systems because of increased risk for serious infections.diphtheria & tetanus toxoidscertolizumab pegol decreases effects of diphtheria & tetanus toxoids by pharmacodynamic antagonism. Use Caution/Monitor.diphtheria & tetanus toxoids/acellular pertussis/poliovirus, inactivated vaccinecertolizumab pegol decreases effects of diphtheria & tetanus toxoids/acellular pertussis/poliovirus, inactivated vaccine by pharmacodynamic antagonism. Use Caution/Monitor.fingolimodcertolizumab pegol increases effects of fingolimod by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Concomitant therapy is expected to increase the risk of immunosuppression. Use caution when switching patients from long-acting therapies with immune effects. .fingolimod and certolizumab pegol both increase immunosuppressive effects; risk of infection. Use Caution/Monitor.haemophilus influenzae type b vaccinecertolizumab pegol decreases effects of haemophilus influenzae type b vaccine by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Avoid vaccination during chemotherapy or radiation therapy if possible because antibody response might be suboptimal. Patients vaccinated within a 14-day period before starting or during immunosuppressive therapy should be revaccinated =3 months after therapy is discontinued if immune competence has been restored.hepatitis A vaccine inactivatedcertolizumab pegol decreases effects of hepatitis A vaccine inactivated by pharmacodynamic antagonism. Use Caution/Monitor.hepatitis a/b vaccinecertolizumab pegol decreases effects of hepatitis a/b vaccine by pharmacodynamic antagonism. Use Caution/Monitor.hydroxyureahydroxyurea, certolizumab pegol. Other (see comment). Use Caution/Monitor. Comment: Combination may increase risk of immunosuppression.influenza A (H5N1) vaccinecertolizumab pegol decreases effects of influenza A (H5N1) vaccine by pharmacodynamic antagonism. Use Caution/Monitor.influenza virus vaccine (H5N1), adjuvantedcertolizumab pegol decreases effects of influenza virus vaccine (H5N1), adjuvanted by pharmacodynamic antagonism. Use Caution/Monitor.influenza virus vaccine quadrivalentcertolizumab pegol decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Use Caution/Monitor.influenza virus vaccine quadrivalent, cell-culturedcertolizumab pegol decreases effects of influenza virus vaccine quadrivalent, cell-cultured by pharmacodynamic antagonism. Use Caution/Monitor.influenza virus vaccine quadrivalent, recombinantcertolizumab pegol decreases effects of influenza virus vaccine quadrivalent, recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immune response to vaccine may be decreased in immunocompromised individuals.influenza virus vaccine trivalentcertolizumab pegol decreases effects of influenza virus vaccine trivalent by pharmacodynamic antagonism. Use Caution/Monitor.influenza virus vaccine trivalent, recombinantcertolizumab pegol decreases effects of influenza virus vaccine trivalent, recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immune response to vaccine may be decreased in immunocompromised individuals.isavuconazonium sulfatecertolizumab pegol and isavuconazonium sulfate both decrease immunosuppressive effects; risk of infection. Use Caution/Monitor.Japanese encephalitis virus vaccinecertolizumab pegol decreases effects of Japanese encephalitis virus vaccine by pharmacodynamic antagonism. Use Caution/Monitor.meningococcal A C Y and W-135 polysaccharide vaccine combinedcertolizumab pegol decreases effects of meningococcal A C Y and W-135 polysaccharide vaccine combined by pharmacodynamic antagonism. Use Caution/Monitor.meningococcal group B vaccinecertolizumab pegol decreases effects of meningococcal group B vaccine by pharmacodynamic antagonism. Use Caution/Monitor. Individuals with altered immunocompetence may have reduced immune responses to the vaccine.ocrelizumabcertolizumab pegol and ocrelizumab both increase immunosuppressive effects; risk of infection. Use Caution/Monitor. Coadministration of ocrelizumab with high doses of corticosteroids is expected to increase the risk of immunosuppression.ofatumumab SCofatumumab SC, certolizumab pegol. Either increases effects of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Consider the risk of additive immune system effects when coadministering immunosuppressive therapies with coadministration. When switching from therapies with immune effects, take into account the duration and mechanism of action of these therapies when initiating ofatumumab SC.olaparibcertolizumab pegol and olaparib both increase pharmacodynamic synergism. Use Caution/Monitor. Coadministration with other other myelosuppressive anticancer agents, including DNA damaging agents, may potentiate and prolongate the myelosuppressive toxicity. oxaliplatinoxaliplatin and certolizumab pegol both increase immunosuppressive effects; risk of infection. Use Caution/Monitor. Use of oxaliplatin with concomitant immunosuppressants or with impaired immune systems may increased risk for serious infections.ozanimodozanimod, certolizumab pegol. Either increases effects of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Coadministration with immunosuppressive therapies may increase the risk of additive immune effects during therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs in order to avoid unintended additive immunosuppressive effects.pegloticasepegloticase will decrease the level or effect of certolizumab pegol by Other (see comment). Use Caution/Monitor. According to the manufacturer, potential for anti-PEG antibody development that may bind to other pegylated drugs; clinical significance unknownpegvaliasepegvaliase, certolizumab pegol. Other (see comment). Use Caution/Monitor. Comment: The majority of patients treated with pegvaliase develop anti-polyethylene glycol (PEG) IgM and IgG antibodies. Risk of coadministration with different PEGylated products is unknown. There is a case report of anaphylaxis following a medroxyprogesterone acetate